Aug
17
2020
American Journal of Psychiatry Publishes Data From Alkermes’ Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS …